skin clearance
J&J’s Oral IL-23 Drug Icotrokinra Surpasses Sotyktu in Phase 3 Psoriasis Trials
Icotrokinra; JNJ-2113; Johnson & Johnson; IL-23 receptor antagonist; Sotyktu; deucravacitinib; plaque psoriasis; Phase 3 clinical trial; skin clearance; oral peptide; Bristol Myers Squibb